Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Cancer Vaccines01:30

Cancer Vaccines

376
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
376
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies.

Internal medicine (Tokyo, Japan)·2019
Same author

Wine cup stoma anastomosis after extended sleeve lobectomy for central-type squamous cell lung cancer.

Journal of cardiothoracic surgery·2019
Same author

[A Case of Metachronous Ascending Colon Metastasis from Gastric Cancer That Was Difficult to Diagnose].

Gan to kagaku ryoho. Cancer & chemotherapy·2019
Same author

Association of the hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms with prognosis in ovarian clear cell carcinoma.

Journal of ovarian research·2019
Same author

Rhegmatogenous retinal detachment with a giant tear located in the intermediate periphery: Two case reports.

Medicine·2019
Same author

Changes in the nutritional statuses of edentulous elderly patients after new denture fabrication with and without providing simple dietary advice.

Journal of prosthodontic research·2019

Related Experiment Video

Updated: Jul 8, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.0K

[Immunotherapy for Lung Cancer:Current Status and Future Prospects].

Hiroyuki Suzuki1

  • 1Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan.

Kyobu Geka. the Japanese Journal of Thoracic Surgery
|December 13, 2023
PubMed
Summary

Immune checkpoint inhibitors (ICI) have transformed non-small cell lung cancer treatment since 2015, expanding from advanced stages to peri-operative care. This review covers ICI history, current applications, biomarker analysis, and managing immune-related adverse events.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K

Related Experiment Videos

Last Updated: Jul 8, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.0K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K

Area of Science:

  • Oncology
  • Immunology

Background:

  • Immune checkpoint inhibitors (ICI) revolutionized non-small cell lung cancer (NSCLC) treatment starting in 2015.
  • Initially approved for unresectable advanced NSCLC, ICI are now explored for peri-operative settings.

Approach:

  • This review synthesizes the historical development of cancer immunotherapy.
  • It summarizes the current clinical applications of ICI in advanced NSCLC.
  • The review also examines the evolving role of ICI in peri-operative treatment strategies.

Key Points:

  • Biomarker analysis is crucial for predicting and optimizing ICI response in NSCLC.
  • Effective management of immune-related adverse events (irAEs) is essential for patient safety and treatment continuity.
  • The scope of ICI therapy in NSCLC has broadened significantly over the past nine years.

Conclusions:

  • ICI represent a major advancement in NSCLC management, with ongoing research expanding their therapeutic potential.
  • Understanding biomarkers and managing irAEs are critical components for successful ICI implementation.
  • The integration of ICI into peri-operative treatment signifies a new frontier in lung cancer care.